NO20021821D0 - Natrium-hydrogen utvekslingstype 1 inhibitor krystaller - Google Patents

Natrium-hydrogen utvekslingstype 1 inhibitor krystaller

Info

Publication number
NO20021821D0
NO20021821D0 NO20021821A NO20021821A NO20021821D0 NO 20021821 D0 NO20021821 D0 NO 20021821D0 NO 20021821 A NO20021821 A NO 20021821A NO 20021821 A NO20021821 A NO 20021821A NO 20021821 D0 NO20021821 D0 NO 20021821D0
Authority
NO
Norway
Prior art keywords
sodium
exchange type
hydrogen exchange
inhibitor crystals
crystals
Prior art date
Application number
NO20021821A
Other languages
English (en)
Norwegian (no)
Other versions
NO20021821L (no
Inventor
Lyle Robinson Brostrom
Terrence Joseph Connolly
Zheng Jane Li
Susan Lee Orrill
Bharat Kiritkumar Shah
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20021821L publication Critical patent/NO20021821L/no
Publication of NO20021821D0 publication Critical patent/NO20021821D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Surgery (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
NO20021821A 1999-10-29 2002-04-18 Natrium-hydrogen utvekslingstype 1 inhibitor krystaller NO20021821D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16237499P 1999-10-29 1999-10-29
PCT/IB2000/001460 WO2001030759A2 (en) 1999-10-29 2000-10-09 Sodium-hydrogen exchanger type 1 inhibitor crystals

Publications (2)

Publication Number Publication Date
NO20021821L NO20021821L (no) 2002-04-18
NO20021821D0 true NO20021821D0 (no) 2002-04-18

Family

ID=22585355

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021821A NO20021821D0 (no) 1999-10-29 2002-04-18 Natrium-hydrogen utvekslingstype 1 inhibitor krystaller

Country Status (44)

Country Link
EP (1) EP1224179B1 (cs)
JP (1) JP2003512455A (cs)
KR (1) KR100464526B1 (cs)
CN (2) CN1205205C (cs)
AP (1) AP2002002493A0 (cs)
AR (1) AR029402A1 (cs)
AT (1) ATE271047T1 (cs)
AU (1) AU778573B2 (cs)
BG (1) BG106729A (cs)
BR (1) BR0015275A (cs)
CA (1) CA2389020A1 (cs)
CO (1) CO5271714A1 (cs)
CZ (1) CZ20021332A3 (cs)
DE (1) DE60012208T2 (cs)
DK (1) DK1224179T3 (cs)
DZ (1) DZ3463A1 (cs)
EA (1) EA004937B1 (cs)
EE (1) EE200200227A (cs)
ES (1) ES2222923T3 (cs)
GE (1) GEP20043222B (cs)
GT (1) GT200000180A (cs)
HK (1) HK1048472B (cs)
HR (1) HRP20020366B1 (cs)
HU (1) HUP0204009A3 (cs)
IL (1) IL148581A0 (cs)
IS (1) IS6302A (cs)
MA (1) MA26840A1 (cs)
MX (1) MXPA02004358A (cs)
NO (1) NO20021821D0 (cs)
NZ (1) NZ517738A (cs)
OA (1) OA12080A (cs)
PA (1) PA8505501A1 (cs)
PE (1) PE20010764A1 (cs)
PL (1) PL354869A1 (cs)
PT (1) PT1224179E (cs)
SI (1) SI1224179T1 (cs)
SK (1) SK5312002A3 (cs)
SV (1) SV2002000209A (cs)
TN (1) TNSN00210A1 (cs)
TR (1) TR200201167T2 (cs)
UA (1) UA72002C2 (cs)
WO (1) WO2001030759A2 (cs)
YU (1) YU31502A (cs)
ZA (1) ZA200203295B (cs)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441176B1 (en) 1999-10-29 2002-08-27 Pfizer Inc. Method for preparing sodium-hydrogen exchanger type 1 inhibitor
HUP0302860A2 (hu) * 2001-01-31 2003-12-29 Pfizer Products Inc. Nátrium-hidrogén cserélő 1-típusú inhibitor hatású vegyület új etanolátjai, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
EP1472242A1 (en) * 2002-01-30 2004-11-03 Pfizer Products Inc. Zoniporide mesylate pharmaceutical compositions and processes for improving solubility of zoniporide
MXPA04008646A (es) * 2002-05-02 2004-12-06 Pfizer Prod Inc Tratamiento para la diabetes y complicaciones diabeticas con inhibidores del nhe-1.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ504769A (en) * 1998-02-27 2005-04-29 Pfizer Prod Inc N-[(substituted five-membered di- or triaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia

Also Published As

Publication number Publication date
BR0015275A (pt) 2002-07-16
EP1224179B1 (en) 2004-07-14
ATE271047T1 (de) 2004-07-15
NO20021821L (no) 2002-04-18
CO5271714A1 (es) 2003-04-30
CN1636991A (zh) 2005-07-13
OA12080A (en) 2003-08-25
AU7441500A (en) 2001-05-08
CA2389020A1 (en) 2001-05-03
DE60012208D1 (de) 2004-08-19
KR100464526B1 (ko) 2005-01-03
CN1205205C (zh) 2005-06-08
GT200000180A (es) 2002-04-11
HK1048472A1 (en) 2003-04-04
PE20010764A1 (es) 2001-07-23
AR029402A1 (es) 2003-06-25
CN1384829A (zh) 2002-12-11
HK1048472B (zh) 2005-09-16
EA004937B1 (ru) 2004-10-28
IL148581A0 (en) 2002-09-12
NZ517738A (en) 2005-06-24
BG106729A (bg) 2002-12-29
HRP20020366B1 (en) 2005-04-30
WO2001030759A2 (en) 2001-05-03
DZ3463A1 (fr) 2001-05-03
SI1224179T1 (en) 2004-10-31
AU778573B2 (en) 2004-12-09
TNSN00210A1 (fr) 2005-11-10
MA26840A1 (fr) 2004-12-20
HRP20020366A2 (en) 2004-02-29
MXPA02004358A (es) 2002-11-07
EP1224179A2 (en) 2002-07-24
HUP0204009A3 (en) 2004-07-28
JP2003512455A (ja) 2003-04-02
KR20020040918A (ko) 2002-05-30
PL354869A1 (en) 2004-03-08
HUP0204009A2 (hu) 2003-03-28
TR200201167T2 (tr) 2002-08-21
AP2002002493A0 (en) 2002-06-30
PA8505501A1 (es) 2003-09-05
WO2001030759A3 (en) 2001-09-13
EE200200227A (et) 2003-06-16
GEP20043222B (en) 2004-04-26
EA200200416A1 (ru) 2002-10-31
SV2002000209A (es) 2002-07-16
CZ20021332A3 (cs) 2002-10-16
SK5312002A3 (en) 2003-01-09
UA72002C2 (en) 2005-01-17
ZA200203295B (en) 2003-06-25
DE60012208T2 (de) 2005-07-21
IS6302A (is) 2002-03-15
DK1224179T3 (da) 2004-10-25
ES2222923T3 (es) 2005-02-16
PT1224179E (pt) 2004-10-29
YU31502A (sh) 2004-12-31

Similar Documents

Publication Publication Date Title
ATE245142T1 (de) No-synthase inhibitoren
DE60012822D1 (de) Wärmetauscher
EE200200273A (et) Uudsed diabeedivastased agensid
NO20004212L (no) Kjølesystem
NO20016319D0 (no) VLA-4 inhibitor-forbindelser
DE69915289D1 (de) Kühlvorrichtung
DE69924306D1 (de) Wärmetauscher
NO20004213L (no) Kjølesystem
DE50012567D1 (de) Kühlvorrichtung
DE10083636T1 (de) Wärmetauscher
DE50005074D1 (de) Flüssigkristallines Medium
DK1216284T3 (da) R 22-erstatningskölemiddel
DE59910800D1 (de) Kühler
DE60027489D1 (de) Wärmetauscher
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
ID27766A (id) Garam-garam paroksetin
NO20021821D0 (no) Natrium-hydrogen utvekslingstype 1 inhibitor krystaller
NO20025132L (no) Natrium-hydrogen-byttertype 1-inhibitor (NHE-1)
DE69929980D1 (de) Kühlvorrichtung
DE69920662D1 (de) Sibe-kristall
ID27904A (id) Metode untuk menyiapkan inhibitor penukar natrium-hidrogen tipe 1
KR950024082U (ko) 교환기용 보호기반
ATA58798A (de) Wärmetauscherblock
ID25793A (id) Garam-garam paroksetin
FIU980019U0 (fi) Juomavesiautomaatti

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application